The transcriptional coactivator SRC-3 plays a key role to enhance prostate cancer (CaP) cell proliferation. Although SRC-3 is highly expressed in advanced CaP, its role in castration resistant CaP (CRPC) driven by PTEN mutation is unknown. We documented elevated SRC-3 in human CRPC and in PTEN-negative human CaP. Patients with high SRC-3 and undetectable PTEN exhibited decreased recurrence-free survival. To explore the causal relationship in these observations, we generated mice in which both Pten and SRC-3 were inactivated in prostate epithelial cells (Pten3CKO mice), comparing them to mice in which only Pten was inactivated in these cells (PtenCKO mice). SRC-3 deletion impaired cellular proliferation and reduced tumor size. Notably, while castration of PtenCKO control mice increased the aggressiveness of prostate tumors relative to non-castrated counterparts, deletion of SRC-3 in Pten3CKO mice reversed all these changes. In support of this finding, castrated Pten3CKO mice also exhibited decreased levels of phospho-Akt, S6 kinase (RPS6KB1) and phosphorylated S6 protein (RPS6), all of which mediate cell growth and proliferation. Moreover, these tumors appeared to be more differentiated as evidenced by higher levels of Fkbp5, an AR-responsive gene that inhibits Akt signaling. Lastly, these tumors also displayed lower levels of certain androgen-repressed genes such as cyclin E2 and MMP10. Together, our results show that SRC-3 drives CRPC formation and offer preclinical proof of concept for a transcriptional coactivator as a therapeutic target to abrogate CRPC progression.
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INTRODUCTION
Prostate cancer (CaP) is the most commonly diagnosed cancer and the leading cause of cancer death in American men. Virtually all mortality results from advanced tumors that invade adjacent organs and metastasize to distant sites. Androgen ablation therapy is the first-line treatment for advanced CaP. Despite transient regression, most tumors recur and become hormone-refractory with androgen-independent phenotype termed "castration resistant CaP" (CRPC). Since the molecular basis of CRPC remains unknown, a mechanistic understanding of its formation will be crucial for designing novel CRPC therapies.
Steroid Receptor Coactivator-3 (SRC-3, AIB1, ACTR or NCOA3) is a member of the p160 SRC family (1) . Members of this family, which also includes SRC-1 (NCOA1) and SRC-2 (TIF2, GRIP1 or NCOA2), mediate transcriptional functions of nuclear receptors and other transcription factors like E2F1, PEA3 and AP-1 (2) (3) (4) (5) . While SRC-1 amplification in human cancer is rare, amplification of the SRC-2 or SRC-3 gene in human cancers is frequent (1, 6, 7) .
In breast cancer, SRC-3 is an established oncogene. Clinical studies have revealed SRC-3 amplification significantly correlates with tumor size. SRC-3 is overexpressed in 35% of ductal carcinoma in situ (DCIS), 31% of invasive tumors and 38% of metastatic disease (1, 8) . In mice, knockout of SRC-3 decreases somatic growth and mammary gland development (9, 10) and delays v-Ha-ras-induced breast cancer initiation and progression (11) . Conversely, SRC-3 overexpression results in spontaneous mouse mammary tumors, as well as tumors in other organs (12) . SRC-3 also promotes other hormone-related cancers such as endometrial carcinoma and ovarian cancer, in addition to hormone-independent esophageal squamous cell carcinoma, gastric 4 cancer, colorectal carcinoma and pancreatic cancer (13) .
In CaP, increased SRC-3 expression is associated with a more aggressive phenotype and worse prognosis (14, 15) . In addition, studies in CaP cell lines like LNCaP and PC-3 have highlighted the relevance of SRC-3 in promoting CaP proliferation through IGF-Akt signaling pathway (16) . SRC-3 also promotes CaP cell migration and invasion by coactivating transcriptional activity of AP-1 and PEA3, transcription factors that upregulate targets including MMPs (17) . Our group has demonstrated that global knockout of SRC-3 in TRAMP (transgenic adenocarcinoma of the mouse prostate) mice arrested prostate tumor progression at the welldifferentiated stage (18) . One caveat of this model lies in the fact that global SRC-3 knockout causes somatic growth retardation accompanied by significant decrease in IGF-1 level (9, 19) .
This makes it difficult to distinguish the cell-autonomous role of SRC-3 from possible impact of systemic factors such as IGF-1. In addition, the function of SRC-3 in CRPC has not been investigated.
The PTEN tumor suppressor gene is mutated in 50% of human CaP. In addition, 70% of late stage CaP show altered PTEN/PI3K/AKT pathway (7) . The mouse model harboring prostate-specific deletion of Pten faithfully mimics human CaP, recapitulating well-defined stages of hyperplasia, prostatic intraepithelial neoplasia (PIN) and invasive carcinoma (20) .
Since SRC-3 plays a key role in CaP but has not been investigated in the setting of PTEN deletion and/or castration, we aim to characterize the expression and molecular interaction relationships between SRC-3 and PTEN in human and mouse CaP, while also defining the role of SRC-3 in CRPC development. We report here that SRC-3 expression is elevated in human ) was previously generated in our lab (21) . Pten f/f mice were reported previously (20) and obtained from Jackson Laboratory. ARR2PBi-Cre (PbCre) mice were described previously (22) . 
Castration
Twelve-week-old male mice were anesthetized by i.p. injection of Avertin (2.5% in saline, 15 μl/g body weight). Mice were castrated via a scrotal incision as described (18) .
Tissue analysis
Prostate tumors in experimental and control mice were analyzed at 9, 12, 18 and 24 weeks of age. Prostate tumors in mice for the androgen deprivation experiment were examined 6 weeks post-castration. The lower urogenital tracts were dissected out in a Petri dish containing phosphate-buffered saline (PBS). Prostate tissues were isolated and each lobe was separated and weighed. Prostate lobes from one side were fixed in 4% paraformaldehyde at 4 o C overnight, dehydrated, processed, paraffin-embedded, and sectioned in 5-μm thickness for H&E staining, 7 Trichrome staining and immunohistochemistry. Lobes from the other side were frozen in liquid nitrogen and stored at -80 o C for RNA and protein analyses.
Histology and immnuohistochemistry
Tissue sections were stained with H&E and Trichrome as described previously (18, 23) .
For immunohistochemistry, antigen retrieval was performed (in a microwave oven) using 10 mM sodium citrate, pH6. The sections were then rinsed with PBS and blocked with either 10% 
RNA isolation and qRT-PCR analysis
Total RNA was prepared from frozen prostate tissues using the TRIzol reagent (Life technologies). cDNA was generated using Eurogen reverse transcriptase kit and real time quantitative RT-PCR (qRT-PCR) analysis was performed using the TaqMan system (Roche).
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Immunoblotting
Dissected mouse prostate samples were snap-frozen in liquid nitrogen. Protein was isolated in RIPA buffer (150 mM NaCl, 1.0% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS and 50 mM Tris-HCl; pH 8.0). Twenty μg of each protein sample was loaded per lane in a polyacrylamide gel. Primary antibodies for immunoblotting were against phospho-Akt (Cell Signaling, #4060), Akt (Cell Signaling, #9272), SRC-3 (Cell Signaling, #2126), phospho-S6 ribosomal protein (Cell Signaling, #5364), S6 Ribosomal protein (Cell Signaling, #2217), p70 S6 Kinase (Cell Signaling, #2708) and β-actin (Sigma, A1978). medium containing 10% FBS. SRC-3 knockdown was achieved by transfection with siGENOME SMARTpool siRNAs targeting hSRC-3 (Dharmacon), using Lipofectamine 2000 (Invitrogen). Non-targeting siRNAs (siGENOME SMARTpool control) was used as the control.
Databases and statistical analysis
We used Cancer Microarray datasets in Oncomine database to study the expression profiles of SRC-3, PTEN and S6K1 in human CaP (24) . The gene expression data were log transformed, median centered per array and the standard deviation was normalized to one per array. The database results were analyzed using GraphPad Prism Software (San Diego, USA).
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Statistical analysis comparisons were done with Student's t-test for tissue weight and gene expression.
RESULTS
SRC-3 expression correlates negatively with PTEN expression and prostate-specific antigen (PSA) recurrence-free survival in CaP patients
We downloaded two sets of expression data published by Tomlins et al. and Chandra et al. (25, 26) from Oncomine database (24) and compared SRC-3 expression between primary prostate tumors and CRPC samples. In both data sets, SRC-3 mRNA expression is significantly higher in CRPC tumors versus primary tumors (Fig. 1A, B) , suggesting SRC-3 may play an important role in CaP progression. Statistical analysis of Tomlins's data also showed SRC-3 expression is negatively associated with PTEN expression (Fig. 1C) . Analysis of another Oncomine data set published by Grasso et al. (27) further demonstrated an elevated SRC-3 mRNA in prostate tumors with PTEN deletion (Fig. 1D) . At the protein level, SRC-3 and PTEN had been examined by IHC in a set of tissue microarrays from 480 radical prostatectomy specimens in Dr. Ittmann's laboratory, although data on these two proteins were reported separately (15, 28) . Here, analysis of these protein expression data revealed a significant negative correlation between higher SRC-3 expression (index > 4) and PTEN levels (rho = -0.156; p = 0.013; Spearman's) in the same CaP cohort. Furthermore, we found patients with high SRC-3 and no PTEN protein had a significantly higher risk of PSA recurrence versus patients with low SRC-3 and any PTEN levels (p<0.0001). Patients with high SRC-3 and detectable PTEN proteins were not significantly different from either group, possibly due to small sample size (number of events = 7), however it appeared more similar to the low risk group with low SRC-3 and any PTEN levels (p=0.2850) rather than the high risk group with high SRC-3 and no PTEN (p=0.0703) (Fig. 1E) . These results indicate SRC-3 expression positively correlates with CRPC development and negatively correlates with PTEN expression and PSA recurrence-free survival of CaP patients. LECs but retained in some basal cells ( Fig. 2A) . SRC-3 mRNA was reduced about 50% versus PtenCKO prostates (Fig. 2B ). This is consistent with LEC-specific SRC-3 deletion, with SRC-3 retention in the basal and stromal compartments. We assessed the impact of SRC-3 ablation on tumor growth by comparing weights of Pten3CKO and PtenCKO prostates harvested at 6, 9, 12, 11 histology was not markedly different between groups, with the exception of an increase in large cystic spaces seen in PtenCKO prostates at 18 week (Fig. 2D) .
Conditional knockout of
To understand the cause of the tumor size difference, we quantified cellular proliferation and apoptosis. Ki67 immunohistochemistry detected nearly twice as many proliferating cells in 
Castration increases cellular proliferation, stromal reactivity and tumor cell dedifferentiation in Pten loss-induced mouse CaP
We evaluated tumor progression and determined that epithelial hyperplasia, low PIN, high PIN and cancer developed in PtenCKO mice at 6, 9, 12 and 18 weeks of age, respectively (Fig. 4A ). Therefore, in order to establish a CRPC model we surgically castrated PtenCKO mice 12 at 12 weeks of age so that tumors would develop from the high PIN stage in an androgendepleted environment. Previous reports demonstrate that PtenCKO prostate tumors initially respond to androgen ablation, as indicated by increased cell death and reduced size. However, after prolonged castration, tumors re-grow and develop into CRPC (20) . In the current study, we analyzed tumors at 18 weeks of age. We found that prolonged castration indeed increased cellular proliferation, while also promoting stromal infiltration and disorganized PEC morphology (Fig. 4B ). Invasive adenocarcinoma increases reactive stroma by inducing a desmoplastic response in which collagen is deposited in the surrounding stromal tissue (23) .
Therefore, we measured this response using Mason's Trichrome, which stains collagen blue and fibrin pink. We found significantly increased blue staining in tumors from castrated versus noncastrated mice (Fig. 4C ). Another marker for reactive stroma is SMA. Loss of the dense SMA layer usually corresponds with tumor invasiveness. Here, we found SMA distribution in castrated tumors is less dense and exhibits a disorganized multilayer pattern, while staining in the noncastrated tumor is a dense, well-defined monolayer boundary that surrounds PECs (Fig. 4C ). In addition, immunohistochemistry for angiogenesis marker CD31 identified significantly more endothelial cells in tumors from castrated versus non-castrated mice (Fig. 4C) . These results suggest castration of PtenCKO mice increases cellular proliferation and aggressiveness of prostate tumors.
To further characterize the castration-induced phenotype, we performed immunohistochemistry for epithelial differentiation markers such as AR, p63 and E-cadherin.
AR is more widely expressed in tumor cells of non-castrated mice, also stained more intensely in these cells versus those of castrated mice. Conversely, the number of p63(+) basal cells is higher in tumors of castrated mice. E-cadherin expression is lower in individual cells in castrated versus When prostate and tumor samples were analyzed at 18 weeks of age (6 weeks postcastration), we found that tumors from Pten3CKO mice were much smaller than those from PtenCKO mice. Pten3CKO prostates were only 30% the weight of PtenCKO prostates (Fig. 5A ). 
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vimentin(+) cells were detected and SMA immunostaining signal showed a monolayer surrounding the ductal glands (Fig. 5C ). Trichrome staining also revealed significant collagen deposit in PtenCKO tumors, while none were present in Pten3CKO tumors (Fig. 5D ). E-cadherin, an epithelial marker, was higher in Pten3CKO than PtenCKO tumors, while immunostaining for CD31, which indicates the extent of angiogenesis, demonstrated more blood vessels in PtenCKO versus Pten3CKO tumors (Fig. 5D) . Taken together, these results demonstrate that specific deletion of SRC-3 inhibits reactive stromal infiltration and tumor cell de-differentiation in castrated mice.
SRC-3 deletion downregulates Akt-mTOR signaling in CRPC tumors
We next aimed to elucidate the molecular mechanism by which SRC-3 promotes cell proliferation, tumor growth and CRPC progression. It is known that SRC-3 enhances Akt activation by up-regulating multiple components of the IGF-I-signaling pathway in breast and prostate cancers (11, 16) . Indeed, tumors from castrated Pten3CKO mice had significantly reduced phosphorylated Akt versus tumors from castrated PtenCKO mice (Fig. 6A) , suggesting SRC-3 is also required for Pten loss-induced Akt activation in the setting of castration.
Phosphorylated ribosomal protein S6 (pRPS6) is an indicator of Akt-mTOR pathway activity.
Immunohistochemistry demonstrated that pRPS6 was widely distributed in the prostatic epithelial and tumor cells of PtenCKO mice but reduced more than 7-fold in the same cell populations of Pten3CKO mice (Fig. S3) . Innunoblotting performed on whole-tumor lysates confirmed this finding (Fig. 6B) . RPS6 is phosphorylated by S6 kinase 1 (S6K1), a protein with both cytosolic (p70) and nuclear (p85) isoforms generated from alternative usage of two ATG codons within the same mRNA (29) . We found that, while the level of cytosolic p70S6K1 was unchanged between PtenCKO and Pten3CKO tumors, the level of nuclear p85S6K1 was significantly lower in Pten3CKO tumors (Fig. 6B) . In cultured AR-negative PC-3 CaP cells, SRC-3 knockdown also reduced phospho-Akt, pRPS6, as well as p70S6K1 and p85S6K1 kinases (Fig. 6C) . These results indicate that in CRPC, SRC-3 knockout inhibits the Akt-mTOR pathway, potentially at multiple steps.
We next assessed S6K1 at the mRNA level in vivo. S6K1 mRNA was reduced 40% in Pten3CKO tumors versus PtenCKO tumors from castrated mice (Fig. 6D) . To evaluate the relationship between SRC-3 and S6K1 expression in human CaP, we downloaded a set of data with clear readouts of both SRC-3 and S6K1 mRNA expression in prostate tumors from Oncomine by Taylor et al (7) . Analysis of this data set indicated SRC-3 expression positively correlated with S6K1 mRNA expression in human prostate tumors (p<0.0001) (Fig. 6E) . These results support the notion that SRC-3 promotes S6K1 expression in CaP, although it is currently unclear whether S6K1 is a direct or indirect SRC-3-regulated gene. (31) . In order to investigate the impact of SRC-3 on AR signaling in vivo, we compared androgen signaling in PtenCKO and Pten3CKO prostate tumors from castrated mice at 18 weeks of age. AR protein levels were comparable between the two tumor types (Fig. S4A) . 
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We then evaluated a group of differentiation genes including probasin, Nkx3.1, FKBP5, Ets2 and Igfbp-3 (30). Among AR-activated genes, the expression levels of probasin and Nkx3.1 were similar in the two tumor types (Fig. S4B) , while the expression of Fkbp5, a specific inhibitor of Akt signaling, was significantly increased in Pten3CKO versus PtenCKO tumors from castrated mice (Fig. 7A) . AR-repressed genes such as Ets2 and Igfbp-3 were significantly downregulated in Pten3CKO versus PtenCKO tumors from castrated mice at 18 weeks (Fig. 7B) . Furthermore, a broader panel of AR-repressed genes that were previously reported to be overexpressed in human CRPC (32) was evaluated and the results were summarized in Fig. 7C . Among these genes, TK1 expression was significantly upregulated in Pten3CKO versus PtenCKO tumors, while MMP10
and cyclin E2 expression levels were significantly lower in Pten3CKO versus PtenCKO tumors in castrated mice (Fig. 7C ). These results demonstrate that SRC-3 knockout causes an increase in expression of specific AR-activated genes while yielding either increases or decreases in certain AR-repressed genes.
DISCUSSION
Advanced CaP responds initially to androgen deprivation therapy but eventually recurs as hormone-refractory CRPC. Since CRPC is highly metastatic and incurable, understanding its molecular mechanism is crucial for designing effective therapies for advanced CaP. The SRC family members coactivate nuclear receptors such as estrogen receptor and AR (1, 6, 7) and other transcription factors like E2F1, AP-1 and PEA3 to drive cancer growth and progression (1- 18 score and negatively with prognosis (14, 15, 35) . Here, we demonstrate elevated SRC-3 expression in human CRPC and CaP with PTEN deletion and its negative correlation with PTEN expression. Moreover, we show patients with tumors characterized by high SRC-3 and no PTEN expression have worse recurrence-free survival rates than patients with detectable PTEN and either low or high SRC-3 expression. These findings suggest SRC-3 can cooperate with PTEN loss to promote CRPC development, resulting in poor recurrence-free survival.
We previously reported global knockout of murine SRC-3 caused arrest of SV40 T/tinduced prostate tumor progression at well-differentiated stages (18) . Here, we demonstrate 
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Pten3CKO tumors of castrated mice has no influence on most AR-regulated genes (Fig. S4B and which may partially reduce the inhibitory effect of this pathway on AR signaling pathway since these two pathways are reciprocally inhibited (30, 45) . Conversely, the increased Fkbp5 expression may be partially responsible for SRC-3 knockout-induced inhibition of Akt-mTOR signaling since Fkbp5 inhibits Akt activity through stabilizing Phlpp phosphatase (46) (47) (48) .
In summary, SRC-3 expression is elevated in CRPC and negatively correlated with PTEN expression and recurrence-free survival of CaP patients. SRC-3 is required for CRPC development induced by Pten deficiency in castrated mice. SRC-3 may promote CRPC principally through enhancing Akt activity and S6K1 expression. Therefore, inhibiting SRC-3 is a promising future strategy for abrogating CRPC development resulting from anti-androgen or anti-AR therapy. 
